Leap Therapeutics announces findings from Phase 2 trial of sirexatamab
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Study Overview: Leap Therapeutics presented final results from Part B of the DeFianCe study, a Phase 2 trial evaluating sirexatamab in combination with bevacizumab and chemotherapy for patients with microsatellite stable colorectal cancer who had prior systemic therapy.
Key Findings: In patients with high levels of circulating DKK1, the study found a 38.0% objective response rate (ORR) in the sirexatamab arm compared to 23.7% in the control arm, with a median progression-free survival (mPFS) of 9.03 months versus 7.06 months, and a median overall survival (mOS) not reached in the sirexatamab arm compared to 14.39 months in the control arm.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
